289 related articles for article (PubMed ID: 28027514)
1. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
Liu CY; Huang TT; Huang CT; Hu MH; Wang DS; Wang WL; Tsai WC; Lee CH; Lau KY; Yang HP; Chen MH; Shiau CW; Tseng LM; Chen KF
Eur J Cancer; 2017 Feb; 72():112-123. PubMed ID: 28027514
[TBL] [Abstract][Full Text] [Related]
2. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
5. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
6. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
7. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF
Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
9. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431
[TBL] [Abstract][Full Text] [Related]
10. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
[TBL] [Abstract][Full Text] [Related]
12. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Pallai R; Bhaskar A; Sodi V; Rice LM
Transcription; 2012; 3(6):323-35. PubMed ID: 23117818
[TBL] [Abstract][Full Text] [Related]
13. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
14. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.
Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y
EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
16. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
17. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
[TBL] [Abstract][Full Text] [Related]
18. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
Liu CY; Hsieh FS; Chu PY; Tsai WC; Huang CT; Yu YB; Huang TT; Ko PS; Hung MH; Wang WL; Shiau CW; Chen KF
Br J Haematol; 2017 Jun; 177(5):726-740. PubMed ID: 28340282
[TBL] [Abstract][Full Text] [Related]
20. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
